Advertisement
New Zealand markets closed
  • NZX 50

    11,755.17
    +8.59 (+0.07%)
     
  • NZD/USD

    0.6021
    -0.0013 (-0.21%)
     
  • NZD/EUR

    0.5584
    -0.0010 (-0.18%)
     
  • ALL ORDS

    8,022.70
    +28.50 (+0.36%)
     
  • ASX 200

    7,749.00
    +27.40 (+0.35%)
     
  • OIL

    78.20
    -1.06 (-1.34%)
     
  • GOLD

    2,366.90
    +26.60 (+1.14%)
     
  • NASDAQ

    18,161.18
    +47.72 (+0.26%)
     
  • FTSE

    8,433.76
    +52.41 (+0.63%)
     
  • Dow Jones

    39,512.84
    +125.08 (+0.32%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • Hang Seng

    18,963.68
    +425.87 (+2.30%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • NZD/JPY

    93.7530
    -0.0150 (-0.02%)
     

DISCLOSURE OF LARGE SHAREHOLDING – AQUA-SPARK

Hofseth Biocare ASA
Hofseth Biocare ASA

Reference is made to the stock exchange announcement by Hofseth BioCare ASA (the "Company") on 3 July 2022 regarding completion of a private placement of new shares (the "Private Placement"). In the Private Placement, the Company will issue a total of 35,490,000 new shares.

Aqua-Spark Coöperatieve U.A. applied for and was allocated 10,350,000 shares in the Private Placement at a price per share of NOK 4.  After the issuance of the new shares in the Private Placement, the shareholding of Aqua-Spark will be more than 5% of the Company's share capital.

Following the Private Placement, Aqua-Spark will hold 22,450,000 shares in the Company, corresponding to 5.71% of the shares and votes outstanding after completion of the Private Placement.

This information is subject to the disclosure requirements pursuant to Sections 4-2 and 5-12 of the Norwegian Securities Trading Act.